Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
about
Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic ImplicationsImportance of Apolipoprotein A-I in Multiple SclerosisSphingolipid signaling in metabolic disordersMultiple sclerosis: the role of cytokines in pathogenesis and in therapiesSphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyondDiagnosis and Management of Multiple Sclerosis in ChildrenMultiple sclerosis and pregnancy; What a neurologist may be asked for?Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.Therapeutic interference with leukocyte recirculation in multiple sclerosis.Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions.Chemokine receptor expression by inflammatory T cells in EAE.Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up studyDual destructive and protective roles of adaptive immunity in neurodegenerative disorders.CXCL13 antibody for the treatment of autoimmune disorders.S1P is associated with protection in human and experimental cerebral malariaPeripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple SclerosisMechanisms of immunological tolerance in central nervous system inflammatory demyelination.The imbalance between Treg and Th17 cells caused by FTY720 treatment in skin allograft rejection.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Myeloid cells as target of fingolimod action in multiple sclerosis.Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset.What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulationDisease-modifying therapy of pediatric multiple sclerosis.How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis.Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.Fingolimod for the treatment of relapsing multiple sclerosis.Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.Targeting sphingosine-1-phosphate receptors in cancer.Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.T(H)17 cytokines in autoimmune neuro-inflammation.
P2860
Q26768649-81C0F4ED-67BA-4176-A55B-FCAEBBDB2581Q26774792-3D6E36CD-C20C-4A84-AC66-2D6C7785BE0DQ26992148-C0578D73-364E-4FB9-B539-32AF15610B1BQ27011014-6D973DDA-B516-47E0-B31F-472B1C90B2E4Q27011857-8B17E69C-298A-4869-8EFA-5DDF1813726DQ28069571-D460EF86-5BEA-43F0-A2C8-42DE7C472657Q30428993-965FA4DE-6697-4B97-BBB1-AA616A967885Q30458371-0C88ACDF-4DD7-4343-A4EC-8870F5A1CC38Q30838717-A6EC9440-DCF7-41B9-9BBF-E4F35252D7E4Q30884219-AEF576FA-A9A6-4692-A379-35A569C9A5A0Q31108462-14BA83B1-E0A6-46BA-9E2C-45FEAA63811DQ33699532-D50C3569-07A5-4B79-8BA3-D3660AFAE006Q33846596-ABAD5805-6E15-462B-A8AF-46621CE8DD60Q33881977-D4B013C8-363B-43F6-84CC-65A5B57BA4A3Q34434118-6194A4FC-2ED3-4AB5-A538-1AFD64DE0D59Q35068792-205433D3-D400-4B52-B700-4B77580E189EQ35086918-02DF4606-D939-4F5F-B99D-1EE171384D7EQ35136728-B09D12DE-4D3E-4232-BCDE-337D31B46F8AQ35547287-DFA00AE1-EF65-48A2-865E-EF3B99FA6F68Q35606563-9CA7FDC7-3A24-4590-B567-73DBC96800D0Q35826151-E037DF04-8BB5-4146-ACB7-D2571F002C97Q36095922-97C237B5-4E5C-45FC-B4D0-06753BFFA72DQ36104096-C2E1061D-63F8-4C5A-8D78-C1165D547ECEQ36223650-8CD6E554-A7E5-4262-8E8D-00DE24D3AB27Q36255283-23881949-0EF2-46E6-876A-3328ED13893CQ36277359-86A65D65-6BBF-4887-9CFA-021BD28ADE99Q36396476-FE0EF301-638D-4AFB-A142-724509292111Q36416533-977A00E1-D473-4004-BF19-DC15400F2983Q36568645-56E9A8F7-F7F0-422C-A177-65BA77D210F5Q36806028-F7561437-8630-4D16-8FD2-0CBF4E61446DQ36960355-D94A7CB2-65D2-4786-8D25-5A10046CC406Q37071787-5FA946BF-803C-4BBE-A521-BFED24DE7571Q37148742-B6CE6F7C-E869-4DC1-80C4-16A29DD18254Q37622730-6670F7F8-1B08-4D11-A71A-DE641356B7BDQ37821010-5B3E25C4-AFA6-494D-B324-8EEFF621CBAAQ37851885-6D658FE9-49FA-4E71-9A1E-8E9CFE382C4EQ37894772-A095666C-B157-4255-B363-6CEAB5BE87F0Q37905665-824B48E1-A464-442C-BDC9-AE542BA223EFQ37905767-95B30092-4D37-4750-8D51-090421839AE9Q37930157-AD912240-EB4E-4241-9010-8A102D2E7977
P2860
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
@en
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
@nl
type
label
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
@en
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
@nl
prefLabel
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
@en
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
@nl
P2093
P1433
P1476
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
@en
P2093
R Lindberg
V Brinkmann
P304
P356
10.1212/WNL.0B013E3181EBDD64
P407
P577
2010-06-30T00:00:00Z